|Bid||488.85 x 0|
|Ask||0.00 x 0|
|Day's Range||478.20 - 478.20|
|52 Week Range||478.20 - 478.20|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Johnson & Johnson, UnitedHealth, Boeing and Impax Laboratories are among the stocks to watch.
Jim Cramer tracks low-valuation stocks like Johnson & Johnson to argue that the market is cheaper than investors may think.
The number of Tampa Bay billionaires on the Forbes 400 is shrinking. There are four area residents on the 2017 list of richest Americans, two fewer than last year. Overall, the wealthy people on the Forbes 400 are getting richer.
In one of the early disclosures of how three hurricanes have affected health care company earnings.
Acquisitions helped increase revenue in the past year, but a slate of fast-growing pharmaceuticals also chipped in.
Johnson & Johnson increased its 2017 sales and adjusted profit guidance for the third quarter in a row, though net income in the quarter fell due to one-time items and amortization related to the Actelion ...
In the so-called war for talent, US corporations try to lure candidates with cushy new benefits, dazzling work spaces (tree houses, anyone?), and promises of better work-life balance. Johnson & Johnson, the medical supply giant, is trying something that may hold even greater appeal for anyone who’s ever sent a resume into the proverbial black…
Despite a strong earnings beat, not everything went J&J's way in the third quarter.